Glucagon-like peptide 1 receptor agonists (GLP-1RA), such as Ozempic and Wegovy, have been rapidly adopted for the treatment of obesity in both youth and adults. However, despite this rapid adoption and the known GLP-1RA mechanism of action for weight loss, which targets brain circuits responsible for appetite and eating behaviors, almost nothing is known about how these drugs affect the brain in youth who are treated for obesity, or how these drugs affect the brain of youth differently from adults. The goal of the current study is to compare youth and adults with obesity who are treated a GLP-1RA and measure potential difference in GLP-1RA associated change in brain function, appetite, and eating behaviors.

Start Date01 May 2026

Sponsor / Collaborator

University of Colorado Denver

[+1]

NCT07179120

/ Not yet recruitingPhase 2IIT

Male Fertility Preservation: Efficacy Evaluation of GLP-1Receptor Agonist Therapy for Infertility in Obese Males - A Multicenter Clinical Randomized Controlled Trial

Why is this study being done? Obesity can harm men's fertility by lowering sperm quality and hormone levels, making it harder to have children. Weight loss through diet and exercise helps, but it's often hard to stick with. New medicines called GLP-1 receptor agonists, like semaglutide (Ozempic) and tirzepatide (Mounjaro), help people lose weight and improve health. Early studies suggest these drugs might also boost sperm health in obese men, but more proof is needed. This study tests if these drugs can safely improve fertility in obese men who are having trouble conceiving.
What will happen in this study?
This is a 48-week study at several hospitals in China. About 180 men will be randomly assigned to one of three groups:
Group 1: Standard lifestyle changes, like a healthy diet and exercise, guided by experts.
Group 2: Weekly injections of semaglutide, starting low and increasing as tolerated.
Group 3: Weekly injections of tirzepatide, starting low and increasing as tolerated.
All men will have regular check-ups, including blood tests, semen analysis, and weight measurements. We will track sperm quality, hormone levels, weight loss, and whether their partners get pregnant naturally. The study includes an 8-week adjustment period, 24 weeks of treatment, and 16 weeks of follow-up.
Who can join this study? Men aged 20-45 who are married, obese (BMI 28 or higher or waist size 90 cm or more), and have been trying to have a baby for at least a year without success due to low sperm count or poor sperm movement. Their female partners must be under 40 and have no major fertility issues. Men must be willing to attend visits and provide samples. People with serious health problems, recent use of similar drugs, or other causes of infertility (like genetic issues) cannot join.
How long will this study last? The full study lasts 48 weeks (about 11 months), with visits every 4-8 weeks, plus monthly phone check-ins for pregnancy updates.
What are the possible benefits and risks? Benefits: If the drugs work, men may lose weight, improve sperm quality, and have a better chance of their partners getting pregnant naturally. They might also feel healthier overall. Risks: Common side effects include nausea, vomiting, or diarrhea from the drugs, which usually improve over time. Rare risks include pancreas inflammation or gallbladder issues. Lifestyle changes might cause minor injuries from exercise. All side effects will be monitored closely, and participants can quit anytime. Insurance covers any study-related harm.

Start Date01 May 2026

Sponsor / Collaborator

The First Affiliated Hospital of Wenzhou Medical College

NCT07090343

/ Not yet recruitingPhase 3IIT

Semaglutide for Reducing Cardiovascular Events in Patients Undergoing Transcatether Aortic Valve Replacement

This is a Phase III, randomized, double-blind, placebo-controlled, multicenter clinical trial evaluating the safety and efficacy of once-weekly semaglutide 2.4 mg in adult patients undergoing transcatheter aortic valve replacement (TAVR) for severe aortic stenosis (AS) who meet current clinical criteria for semaglutide treatment. A total of 826 participants will be randomized 1:1 to receive semaglutide or placebo as an add-on to standard-of-care, starting 3 months before TAVR and continuing for 24 months post-procedure. The primary endpoint is time to first occurrence of a composite of cardiovascular (CV) death, non-fatal myocardial infarction, non-fatal stroke or transient ischemic accident (TIA), and hospitalization for heart failure (HF). The study is event-driven and powered to detect a 20% relative risk reduction in primary outcome events. This trial aims to address the unmet need for medical therapies that improve outcomes in patients with severe AS following TAVR, with potential for direct clinical implementation.

Start Date01 Apr 2026

Sponsor / Collaborator

Leids Universitair Medisch Centrum

100 Clinical Results associated with Semaglutide (Novo Nordisk)

100 Translational Medicine associated with Semaglutide (Novo Nordisk)

100 Patents (Medical) associated with Semaglutide (Novo Nordisk)

331

Literatures (Medical) associated with Semaglutide (Novo Nordisk)

31 Dec 2025·JOURNAL OF MEDICAL ECONOMICS

Impact of semaglutide 2.4 mg on healthcare resource utilization and medical costs in patients with atherosclerotic cardiovascular disease in the United States (SHINE-ASCVD)

Article

Author: Zhao, Zhenxiang ; Alvarez, Sara ; Michalak, Wojciech ; Faurby, Mads ; Fitch, Angela

BACKGROUND:

Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of morbidity and mortality. Semaglutide 2.4 mg (Wegovy) has demonstrated improved outcomes in patients with overweight or obesity (ov/ob) and ASCVD, but its impact on medical costs and healthcare resource utilization (HCRU) remains unknown.

AIMS:

To compare all-cause medical costs and HCRU among patients with ov/ob and ASCVD treated with semaglutide 2.4 mg versus semaglutide-untreated controls.

MATERIALS AND METHODS:

This observational cohort study utilized Komodo's Healthcare Map and included patients with ov/ob and ≥1 diagnosis of ASCVD during the baseline period with ≥12 months of insurance coverage before and after the index date. Patients in the semaglutide 2.4 mg cohort initiated treatment after 4 June 2021 and stayed adherent. Semaglutide-untreated controls were randomly selected and 1:4 propensity score matched based on baseline demographics, clinical characteristics, medical costs, and HCRU. Medical costs and HCRU were compared using generalized linear models.

RESULTS:

770 semaglutide 2.4 mg-treated patients and 3,080 controls were included. In the year following treatment initiation, semaglutide 2.4 mg was associated with 22% lower mean medical costs versus controls (-$4,639 per patient per year [PPPY]; cost ratio = 0.78, 95% confidence interval [CI] 0.67, 0.89). This difference is mainly due to lower inpatient costs with semaglutide 2.4 mg, which were 65% lower than controls (-$3,593; cost ratio = 0.35 [95% CI 0.21, 0.49]), along with a 48% lower inpatient visit rate (0.08 vs. 0.15; rate ratio = 0.52 [95% CI 0.34, 0.70]).

LIMITATIONS:

Limitations inherent to retrospective claims analyses apply to this study.

CONCLUSIONS:

This real-world analysis shows significantly lower annual medical costs and HCRU with semaglutide 2.4 mg versus no semaglutide 2.4 mg treatment in patients with ov/ob and ASCVD. Improving outcomes with semaglutide 2.4 mg combined with lower costs and HCRU may help slow the growing burden of ASCVD in this population.

01 Dec 2025·NEUROPHARMACOLOGY

GLP-1 receptor agonist semaglutide ameliorates motor deficits and tau pathology in the rTg4510s mouse model

Article

Author: Li, Xin-Yi ; Liu, Feng-Tao ; Xu, Zhi-Heng ; Lin, Hua-Mei ; Zhang, Meng-Wei ; Chen, Chen ; Zuo, Chuan-Tao ; Wu, Jian-Jun ; Zhao, Jue ; Wang, Jian ; Yu, Wen-Bo ; Tang, Yi-Lin ; Zhou, Wan-Yi ; Sun, Yi-Min

BACKGROUND:

Tauopathies, including Alzheimer's disease, are characterized by progressive neurodegeneration manifesting as motor and cognitive impairments. This study evaluated the therapeutic potential of semaglutide, a clinically approved glucagon-like peptide-1 receptor agonist, in the rTg4510 mouse model of tauopathy.

METHODS:

Starting at three months of age, rTg4510 mice and wild-type littermates received semaglutide (0.10 mg kg^-1, intraperitoneal) or vehicle (PBS) every other day for 16 weeks. Motor coordination, anxiety-like behavior, spatial working memory, and associative fear memory were assessed using behavioral paradigms. Tau accumulation was monitored via 18F-PM-PBB3 micro-PET/CT imaging. Immunohistochemistry and immunoblot analyses quantified tau pathology, neuronal integrity, and glial activation.

RESULTS:

Semaglutide significantly improved motor coordination in rTg4510 mice on the pole test, though not rotarod endurance. While spontaneous locomotion, anxiety-like behaviors, and Y-maze spatial working memory remained unchanged, semaglutide significantly enhanced cue-dependent freezing in fear conditioning, indicating improved associative memory. ¹⁸F-PM-PBB3 PET imaging revealed a pronounced reduction in cortical and hippocampal tracer uptake, indicative of reduced tau burden. Immunohistochemistry and Western blotting confirmed significantly decreased cortical phosphorylated tau (AT8) levels. Semaglutide preserved cortical neuronal integrity; however, no hippocampal changes were detected, likely due to minimal baseline neuron loss at this age. Astrocytic (GFAP) and microglial (Iba1) activation remained unaffected.

CONCLUSION:

Semaglutide ameliorated domain-specific motor impairments, enhanced associative fear memory, and attenuated cortical tau pathology in rTg4510 mice. These findings highlight therapeutic promise of semaglutide as a disease-modifying agent for tauopathies, justifying further dose-response, mechanistic, and translational studies.

01 Nov 2025·LIFE SCIENCES

Linking GLP-1 activation with steroidogenesis, redox, endoplasmic reticulum stress, mitophagy, and the apoptotic regulatory network unlocks the emerging impacts of semaglutide on 5-fluorouracil-induced testicular toxicity

Article

Author: Khidr, Haneen Y ; Hassan, Noha F ; Abd El-Galil, Mona M ; Reda, Enji ; Gowifel, Ayah M H ; El-Zohairy, Nahla A ; Eltelbany, Rania Farag A

AIMS:

One of the recent growing complications of neoplastic chemotherapy that is considered a challenge in their therapeutic protocol is testicular dysfunction. The pathogenesis of testicular injury is multifactorial, involving various pathogenic mechanisms, including oxidative stress, endoplasmic reticulum stress (ERS), and mitochondrial dysfunction. Semaglutide (Sema), a GLP1 agonist, is repurposed nowadays in multiple conditions ascribed to its effectiveness in shielding against oxidative stress and ERS, along with boosting mitochondrial biogenesis. Accordingly, this study proposes to investigate the use of Sema as adjunctive therapy in a 5-fluorouracil (5-FU) treatment protocol to diminish its testicular dysfunction complications.

MATERIALS AND METHODS:

Rats were allocated into five groups. Group I: normal control group; Group II was injected with Sema (12 μg/kg, s.c.) once weekly for 30 days. Groups III (5-FU group), IV, and V were injected with 5-FU (20 mg/kg, every other day, i.p.) for 30 days. Group IV (Sema-treated group) was injected with Sema, while group V (Blocker group) was injected with exendin 9-39 (50 μg/kg, once weekly, I.V.).

KEY FINDINGS:

The results revealed that activation of GLP-1 attenuated 5-FU-induced testicular dysfunction by enhancing the PINK-1/Parkin axis and mitochondrial biogenesis, eliminating ERS-related proteins (PERK, ATF6, GRP78, and CHOP). Sema activated the Nrf2/HO-1 hub, improved steroidogenesis and spermatogenesis by elevating STAR/DAZL and serum FSH, LH, and testosterone levels.

SIGNIFICANCE:

This study highlighted the use of Sema as adjunctive therapy in the 5-FU treatment protocol to guard against the associated testicular dysfunction, via modulating oxidative stress, ERS, and mitochondrial dysfunction in the rat experimental model.

2,383

News (Medical) associated with Semaglutide (Novo Nordisk)

15 Oct 2025

·www.fiercebiotech.com

Eli Lilly\'s orforglipron bests Farxiga, padding oral GLP-1 case with pair of phase 3 diabetes wins

If everything goes to plan, Eli Lilly will file for approval of orforglipron in Type 2 diabetes in 2026.\n Eli Lilly has guided its oral GLP-1 drug candidate orforglipron through two more late-phase tests in Type 2 diabetes, racking up wins against placebo and AstraZeneca’s Farxiga to stay on track to seek approval in the indication next year.Lilly has run two sets of phase 3 trials for orforglipron, one to support approval in obesity and another to unlock the diabetes market. The company previously posted diabetes victories over placebo and oral semaglutide, Novo Nordisk’s GLP-1 drug. Wednesday, Lilly shared data from two of the remaining three trials in its diabetes program.One trial compared three doses (3 mg, 12 mg and 36 mg) of orforglipron to dapagliflozin, an SGLT-2 inhibitor that AstraZeneca sells as Farxiga. The trial enrolled adults with Type 2 diabetes inadequately controlled on metformin. At Week 40, patients\' A1C, a measure of blood glucose, fell up to 1.7% on orforglipron and 0.8% on dapagliflozin.The other trial compared the same three doses of orforglipron to placebo in adults with Type 2 diabetes and inadequate glycemic control with titrated insulin glargine. After 40 weeks of treatment, Lilly saw A1C reductions of up to 2.1% in the orforglipron arms, versus a 0.8% decline in the placebo cohort.The A1C reductions were big enough for both trials to hit their primary endpoints. Lilly said the studies also met all key secondary endpoints at 40 weeks. Patients taking orforglipron lost weight and showed improvements in multiple cardiovascular risk factors, although Lilly is yet to share the data for these endpoints. Similarly, Lilly said the safety and tolerability profile was consistent with prior studies without sharing any numbers. Lilly’s A1C data raise questions about the need for the high dose. A1C decreased 1.7% in patients taking 12 mg and 36 mg of orforglipron in the dapagliflozin comparison study. Lilly saw a larger drop in A1C on the middle, 12-mg dose than the top dose in the placebo-controlled trial. A1C fell 2.1% on the middle dose, compared to 1.9% on the top dose. Lilly plans to share more data at a future medical meeting. The topline readout means Lilly\'s drug has now delivered wins in four of the five trials in its phase 3 diabetes program. Data from the final global registration trial are due in the first quarter of next year. If everything goes to plan, Lilly will file for approval of orforglipron in Type 2 diabetes in 2026, adding to an obesity submission that is scheduled for this year.Obesity has dominated the thoughts of investors, who sent Lilly’s share price down when weight loss data fell short of expectations earlier this year. But the company sees diabetes as a big opportunity too. Patrik Jonsson, president of Lilly International, told attendees at a Wells Fargo event last month that “the oral Type 2 market in the U.S. is huge” and orforglipron could be a really good medicine in the indication.

$Eli Lilly\'s orforglipron bests Farxiga, padding oral GLP-1 case with pair of phase 3 diabetes wins$

Clinical ResultPhase 3Drug Approval

15 Oct 2025

·endpoints.news

Lilly’s oral GLP-1 racks up two more clinical wins in diabetes

Eli Lilly’s GLP-1 pill has succeeded in two more late-stage trials in type 2 diabetes. The company said Wednesday that orforglipron beat AstraZeneca’s Farxiga at lowering patients’ blood sugar levels in one trial, and it topped placebo on the same measure in a different study in patients who were also taking insulin. The data bolster the case for the pill’s approval in diabetes that could come next year. In the trial designated ACHIEVE-2, the highest dose of Lilly’s drug cut A1C, a measure of glucose in a patient’s blood, by 1.6% after 40 weeks of treatment. Patients given Farxiga had an A1C reduction of 0.8%. Farxiga is an oral SGLT2 inhibitor approved to treat heart failure, but also to help type 2 diabetes patients control their blood glucose levels. Subjects in ACHIEVE-2 couldn’t maintain glycemic control despite taking metformin, the generic diabetes medication. Hello Sean Cole , Endpoints is fielding its next Pulse Poll — a one-minute check-in on how artificial intelligence is reshaping biopharma. Results are confidential and will feed into our coverage of AI's real-world impact. Hello Sean Cole , Endpoints is fielding its next Pulse Poll — a one-minute check-in on how artificial intelligence is reshaping biopharma. Results are confidential and will feed into our coverage of AI's real-world impact. Hello Sean Cole , Endpoints is fielding its next Pulse Poll — a one-minute check-in on how artificial intelligence is reshaping biopharma. Results are confidential and will feed into our coverage of AI's real-world impact. Hello Sean Cole , Endpoints is fielding its next Pulse Poll — a one-minute check-in on how artificial intelligence is reshaping biopharma. Results are confidential and will feed into our coverage of AI's real-world impact. Hello Sean Cole , Endpoints is fielding its next Pulse Poll — a one-minute check-in on how artificial intelligence is reshaping biopharma. Results are confidential and will feed into our coverage of AI's real-world impact. Hello Sean Cole , Endpoints is fielding its next Pulse Poll — a one-minute check-in on how artificial intelligence is reshaping biopharma. Results are confidential and will feed into our coverage of AI's real-world impact. Hello Sean Cole , Endpoints is fielding its next Pulse Poll — a one-minute check-in on how artificial intelligence is reshaping biopharma. Results are confidential and will feed into our coverage of AI's real-world impact. Hello Sean Cole , Endpoints is fielding its next Pulse Poll — a one-minute check-in on how artificial intelligence is reshaping biopharma. Results are confidential and will feed into our coverage of AI's real-world impact. The study tested three doses of orforglipron — 3 mg, 12 mg and 36 mg, each taken once per day. All doses of orforglipron hit statistical significance versus AstraZeneca’s drug on the A1C measure. Lilly said that the trial hit “all key secondary endpoints” too, showing “significant” weight loss as well as improvements in certain cardiovascular risk factors. It did not detail the data for the secondary endpoints. In the other study, named ACHIEVE-5, the same three doses of orforglipron were given alongside Lilly’s long-acting insulin Basaglar. The combo reduced blood sugar levels by 1.8% in patients who received the highest dose at 40 weeks. Patients given a placebo on top of Basaglar saw their blood sugar fall by 0.8%. Again, the difference was significant at all doses. The trial’s participants were permitted to take metformin and/or SGLT2 inhibitors as background therapy. Lilly’s pill already demonstrated a benefit in its first Phase 3 test in type 2 diabetes patients in April . Additional data backing this use arrived last month, when orforglipron beat Novo Nordisk’s rival GLP-1 pill Rybelsus in a head-to-head battle. The drug was roughly as safe and tolerable as it has been in prior trials, Lilly said. The new data come as a relief to the company after the pill disappointed in one obesity study earlier this year. In fairness, the product performed better in patients with both obesity and diabetes than in patients with obesity alone. There is one last study in the ACHIEVE suite of diabetes trials still left to read out. ACHIEVE-4 is testing the pill head-to-head against Basaglar, seeing if it can reduce the risk of cardiovascular events, including heart attacks, strokes and death. Data could come in the first half of next year. Lilly plans to seek approval of orforglipron for type 2 diabetes in 2026. First, though, it plans to submit an application for the drug’s use in obesity, with that filing coming this year. The drugmaker is also trialing the pill in obstructive sleep apnea, high blood pressure and osteoarthritis pain in adults with obesity.

Clinical ResultPhase 3Drug Approval

15 Oct 2025

·firstwordpharma.com

Lilly's orforglipron adds AstraZeneca's Farxiga to list of bested drugs in diabetes

Eli Lilly on Wednesday reported another success in a study pitting its once-daily oral GLP-1 therapy orforglipron against a competing type 2 diabetes therapy, this time AstraZeneca's SGLT2 inhibitor Farxiga (dapagliflozin). "Orforglipron has now demonstrated superiority over two active comparators," remarked Jeff Emmick, senior vice president of product development at Lilly Cardiometabolic Health.Last month, orforglipron beat Novo Nordisk's oral drug Rybelsus (semaglutide) on both blood glucose control and weight loss in the Phase III ACHIEVE-3 trial.The latest study, dubbed ACHIEVE-2, compared three doses of orforglipron to Farxiga in 962 participants with type 2 diabetes and inadequate glycaemic control with metformin. The trial's main goal was to demonstrate that orforglipron is non-inferior in A1C reduction from baseline after 40 weeks, compared to AstraZeneca's drug.Top-line results showed that all doses of orforglipron met the primary endpoint, as well as all key secondary goals, delivering significant A1C reduction and weight loss, as well as improvements in multiple cardiovascular risk factors. Specifically, the 3-mg dose of orforglipron led to a 1.3% reduction in A1C from baseline, rising to 1.7% for both the 12 mg and 36 mg doses, versus 0.8% for Farxiga.Lilly added that in another late-stage trial, called ACHIEVE-5, orforglipron also met its primary endpoint, as well as all key secondary goals. The study compared the same three doses of orforglipron to placebo in adults with type 2 diabetes and inadequate glycaemic control with titrated insulin glargine, with or without metformin and/or SGLT-2 inhibitors.Head-line data showed that the 3-mg dose of orforglipron led to a 1.5% reduction in A1C from baseline to week 40, while it was 2.1% for the 12-mg dose, 1.9% for the 36-mg dose and 0.8% for placebo."The findings from ACHIEVE-5 add to this momentum, showing significant A1C reduction and weight loss when used in combination with titrated basal insulin," Emmick commented.Orforglipron's overall safety and tolerability profile in the two studies, as well as treatment discontinuation rates, were consistent with previous trials, according to Lilly. The most common adverse events were gastrointestinal-related and generally mild-to-moderate in severity, while no hepatic safety signal was observed (for related analysis, see Spotlight On: Lilly brushes aside orforglipron safety scare).Detailed findings from the studies will be presented at a future medical meeting. Results from ACHIEVE-4, the final global registration trial in the ACHIEVE programme, are anticipated in the first quarter of 2026, teeing up marketing applications for orforglipron in type 2 diabetes.Meanwhile, orforglipron submissions for the treatment of obesity are on track to occur by the end of this year. The therapy was discovered by Chugai Pharmaceutical and licensed by Lilly in 2018.

Clinical ResultPhase 3

100 Deals associated with Semaglutide (Novo Nordisk)

External Link

KEGG	Wiki	ATC	Drug Bank
D10025	Semaglutide (Novo Nordisk)	A10BJ06	DB13928

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Cardiovascular Diseases	United States	Novo Nordisk, Inc.	15 Aug 2025
Nonalcoholic Steatohepatitis	United States	Novo Nordisk A/S	15 Aug 2025
Nonalcoholic Steatohepatitis	United States	Novo Nordisk, Inc.	15 Aug 2025
Chronic Kidney Diseases	United States	Novo Nordisk, Inc.	28 Jan 2025
Chronic Kidney Diseases	United States	Novo Nordisk A/S	28 Jan 2025
Stroke	Australia	Novo Nordisk Pharmaceuticals Pty Ltd.	16 Dec 2024
Myocardial Infarction	Canada	Novo Nordisk Canada, Inc.	27 Nov 2024
Obesity	United States	Novo Nordisk, Inc.	04 Jun 2021
Overweight	United States	Novo Nordisk, Inc.	04 Jun 2021
Diabetes Mellitus, Type 2	United States	Novo Nordisk, Inc.	05 Dec 2017

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Albuminuria	Phase 3	Canada	Novo Nordisk A/S	14 Mar 2022
Albuminuria	Phase 3	Germany	Novo Nordisk A/S	14 Mar 2022
Albuminuria	Phase 3	Netherlands	Novo Nordisk A/S	14 Mar 2022
Albuminuria	Phase 3	Spain	Novo Nordisk A/S	14 Mar 2022
Osteoarthritis, Knee	Phase 3	United States	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	Canada	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	Colombia	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	Denmark	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	France	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	Norway	Novo Nordisk A/S	01 Oct 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03574597 (SELECT, Pubmed \| J Med Econ)	Phase 3	Cardiovascular Diseases \| Obesity	-	Semaglutide 2.4 mg	lrobfhvyxv(wgefwdtjad) = kpckjrgrgd tevfaokcpf (xhagecmvfk ) View more	Positive	31 Dec 2025
NCT04916470 (STEP-HFpEF DM, Pubmed \| JACC Heart Fail)	Phase 3	-	1,145	Semaglutide	syjpzqkdql(crjyscexeg): Difference (Semaglutide vs Placebo) = 14.6 (95.0% CI, 8.6 - 20.7), P-Value = < 0.0001 View more	Positive	01 Nov 2025
				Placebo
NCT02970942 \| NCT03552757 \| NCT03548935 (STEP 1, Pubmed \| JHEP Rep)	Phase 2	Nonalcoholic Steatohepatitis	-	Semaglutide 2.4 mg	obhqwinakv(wtfobqbnhv) = pikjzqzrdu xxhyvidpiv (rvzbhkcgak ) View more	Positive	01 Oct 2025
				Semaglutide 1.0 mg	obhqwinakv(wtfobqbnhv) = plskvogufl xxhyvidpiv (rvzbhkcgak ) View more
NCT03914326 (SOUL, CTgov)	Phase 3	Diabetes Mellitus, Type 2 \| Myocardial Infarction \| Heart Diseases ... View more	9,651	Semaglutide (Oral Semaglutide)	ysqbnrawdw = xtfjrteocs glnxmetdqw (lmydljjrki, ibjfpturnc - xsaawfoptz) View more	-	22 Sep 2025
				Placebo (semaglutide) (Placebo)	ysqbnrawdw = leyqamoikk glnxmetdqw (lmydljjrki, pzmufnkvag - opwrmbbsua) View more
NCT05564117 (OASIS 4, Pubmed \| N Engl J Med)	Phase 3	-	307	Oral Semaglutide 25 mg	cbbcrqlund(xwocbssuph) = fnzkszctjf ushhcksvmj (faemrkfial )	Positive	18 Sep 2025
				Placebo	cbbcrqlund(xwocbssuph) = biewfzugww ushhcksvmj (faemrkfial )
NCT04126603 (CTgov)	Phase 4	Diabetes Mellitus, Type 2	10	Placebos (Group A Placebo)	mnnuavrxmp(myctvxnikw) = lokplqikrk pkpvixydpi (wsuwbexuhj, 0.06) View more	-	09 Sep 2025
				Semaglutide (Group B Active)	mnnuavrxmp(myctvxnikw) = amdebusnop pkpvixydpi (wsuwbexuhj, 0.16) View more
NCT05193578 (Pubmed \| JAMA Psychiatry)	Phase 3	Schizophrenia	154	Semaglutide	mlxuqgklgx(rxnpjtmplq) = vlfmgrqizd zdulnjuiju (lptfgpfiue, 1.52 - 5.98) View more	Positive	03 Sep 2025
STEER (PRNewswire \| NEWS) Manual	Not Applicable	Obesity	-	Wegovy 2.4 mg	uvpqzfcajm(omdepgrjxp) = Wegovy showed a significant 29% risk reduction compared with tirzepatide. fusumeykfs (splcknljll ) View more	Positive	01 Sep 2025
				Tirzepatide
NCT06914141 \| NCT06914154 \| NCT06914102 (JAMA) Manual	Not Applicable	Heart failure with normal ejection fraction	97,790	Semaglutide	pqtnpgillb(zctmbscvrm): HR = 0.58 (95.0% CI, 0.51 - 0.65) View more	Positive	31 Aug 2025
				sitagliptin
NCT05537233 (ADJUST-T1D, CTgov)	Phase 2	Diabetes Mellitus, Type 1 \| Obesity	115	Semaglutide (Semaglutide)	eybqanmwbk = dwufwgnmeb qnawqwslcx (wbcfnbtjdf, wgodwaxkgn - hosrxzzlka) View more	-	12 Aug 2025
				Placebo (Control)	eybqanmwbk = myncokjzma qnawqwslcx (wbcfnbtjdf, uhlrfjjzkf - epyolybqpj) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis